{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Response rate is defined as the percentage of patients who have a complete response (CR) or partial response (PR). Responses were assessed every two cycles of treatment, based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006). Per International Myeloma Working Group response criteria:\n\nCR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow PR: \\> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>90% or to \\< 200 mg/24 h","groups":[{"description":"VELCADE given by intravenous push at 1.3 mg/m\\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.\n\nCyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.\n\nChloroquine given at 500 mg orally daily on days 1-14 and 22-35.\n\nEach cycle is 42 days in length.","id":"OG000","title":"Velcade+Cyclophosphamide+Chloroquine"}],"paramType":"NUMBER","populationDescription":"Evaluable patients.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Response Rate (CR + PR After 2 Cycles)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}